Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives
Por:
Egoavil C, Juarez M, Guarinos C, Rodriguez M, Hernandez E, Alenda C, Paya A, Castillejo A, Serradesanferm A, Bujanda L, Fernández-Bañares F, Cubiella J, de-Castro L, Guerra A, Aguirre E, Herreros-de-Tejada A, Bessa X, Herráiz M, Marín-Gabriel JC, Balmaña J, Piñol V, Cuatrecasas M, Balaguer F, Castells A, Soto J, Zapater P and Jover R
Publicada:
1 jul 2017
Ahead of Print:
8 abr 2017
Categoría:
Gastroenterology
Resumen:
BACKGROUND & AIMS: We investigated whether patients with multiple serrated polyps, but not meeting the World Health Organization criteria for serrated polyposis syndrome, and their relatives have similar risks for colorectal cancer (CRC) as those diagnosed with serrated polyposis. METHODS: We collected data from patients with more than 10 colonic polyps, recruited in 2008-2009 from 24 hospitals in Spain for a study of causes of multiple colonic polyps. We analyzed data from 53 patients who met the criteria for serrated polyposis and 145 patients who did not meet these criteria, but who had more than 10 polyps throughout the colon, of which more than 50% were serrated. We calculated age-and sex-adjusted standardized incidence ratios (SIRs) for CRC in both groups, as well as in their first-degree relatives. RESULTS: The prevalence of CRC was similar between patients with confirmed serrated polyposis and multiple serrated polyps (odds ratio, 1.35; 95% confidence interval [CI], 0.64-2.82; P=.40). The SIR for CRC in patients with serrated polyposis (0.51; 95% CI, 0.01-2.82) did not differ significantly from the SIR for CRC in patients with multiple serrated polyps (0.74; 95% CI, 0.20-1.90; P=.70). The SIR for CRC also did not differ significantly between first-degree relatives of these groups (serrated polyposis: 3.28, 95% CI, 2.16-4.77; multiple serrated polyps: 2.79, 95% CI, 2.10-3.63; P =.50). Kaplan-Meier analysis showed no differences in the incidence of CRC between groups during the follow-up period (log-rank, 0.6). CONCLUSIONS: The risk of CRC in patients with multiple serrated polyps who do not meet the criteria for serrated polyposis, and in their first-degree relatives, is similar to that of patients diagnosed with serrated polyposis.
Filiaciones:
Egoavil C:
Research Laboratory, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Juarez M:
Research Laboratory, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Guarinos C:
Research Laboratory, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Rodriguez M:
Service of Digestive Medicine, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Hernandez E:
Research Laboratory, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Alenda C:
Pathology Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Paya A:
Pathology Department, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Castillejo A:
Molecular Genetics Laboratory, Elche University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Elche, Spain
Serradesanferm A:
Institut de Malaties Digestives i Metabòliques. CIBERehd. Hospital Clínic. Barcelona. Spain
Bujanda L:
Gastroenterology Department. Hospital Donostia. CIBERehd. Universidad del País Vasco. San Sebastián. Spain
Fernández-Bañares F:
Gastroenterology Department. Hospital Mútua de Terrassa. Terrassa. Spain
Cubiella J:
Gastroenterology Department. Complexo Hospitalario Universitario de Ourense. Ourense. Spain
de-Castro L:
Gastroenterology Department. Complexo Hospitalario de Vigo. Vigo. Spain
Guerra A:
Gastroenterology Department. Complejo Hospitalario de Navarra. Pamplona. Spain
Aguirre E:
Oncology Department. Hospital Arnau de Vilanova. Lleida. Spain
Herreros-de-Tejada A:
Gastroenterology Department. Hospital Puerta de Hierro. Madrid. Spain
Bessa X:
Gastroenterology Department. Hospital del Mar. Barcelona. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
Herráiz M:
Gastroenterology Department. Clínica Universitaria de Navarra. Pamplona. Spain
Marín-Gabriel JC:
Gastroenterology Department. Hospital 12 de Octubre. Madrid. Spain
Balmaña J:
Oncology Department. Hospital Vall d'Hebrón. Barcelona. Spain
Piñol V:
Gastroenterology Department. Hospital Universitari Dr. Josep Trueta, Girona. Spain
Cuatrecasas M:
Pathology Department. Hospital Clínic. Barcelona. Spain
Balaguer F:
Institut de Malaties Digestives i Metabòliques. CIBERehd. Hospital Clínic. Barcelona. Spain
Castells A:
Institut de Malaties Digestives i Metabòliques. CIBERehd. Hospital Clínic. Barcelona. Spain
Soto J:
Molecular Genetics Laboratory, Elche University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Elche, Spain
Zapater P:
Clinical Pharmacology Department, CIBERehd, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain
Jover R:
Service of Digestive Medicine, Alicante University General Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL-FISABIO Foundation), Alicante, Spain.
Bronze
|